BERLIN (AP) - German pharmaceutical company Merck KgaA says a late stage trial of a new lung cancer drug has failed to meet expectations.
The company, based in Darmstadt, says the drug Stimuvax did not improve the overall survival of patients in the phase III study.
Merck shares fell 3.1 percent to (EURO)98.20 ($129.41) after the announcement early Wednesday.
The company is a separate entity from Merck & Co., which is based in the U.S.
'Your papers, please' must never be heard in America
Independent voices from the TWT Communities
Born in 1930 in rural Missouri, Charles Vandegriffe, Sr., brings his time and place to the Communities.
Join the Communities and submit your column in response to one written, or on something totally new and unique. We want to hear from you
Entering the world of first time parents, there are lots of secrets unveiled.
Take a look at our pet friendly reviews and travel tips or find the best vacation deals and activities compiled by the The Washington Times Communities experts.
Benghazi: The anatomy of a scandal
13 Photos
Vietnam Memorial adds four names
18 Photos
Cinco de Mayo on the Mall
11 Photos
